Nova Eye Medical launches iTrack Advance study
Click Here to Manage Email Alerts
The first patient has been enrolled in a prospective, randomized, multicenter study of the iTrack Advance canaloplasty device, according to a press release from Nova Eye Medical.
The CATALYST study will assess the effectiveness, safety and quality of life outcomes of canaloplasty procedures conducted with the device. Up to 80 participants with mild to moderate uncontrolled open-angle glaucoma, who are on between one and four medications, will be enrolled across five sites in Germany.
“The major advantage of this new device for the surgeon is that it allows canaloplasty to be a truly single-handed surgical procedure,” primary study investigator Norbert Koerber, MD, PhD, FEBO, said in the release. “The handpiece features a custom-designed cannula which enables the surgeon to create an opening in the meshwork before using the injector on the handpiece to guide the microcatheter easily into the canal — all using only one hand. We believe this progress in the device design is a crucial step in encouraging more cataract surgeons to perform ab interno canaloplasty in combination with cataract surgery.”
The company expects the study to reinforce the clinical utility of the device to treat mild to moderate glaucoma.
Read more about
Click Here to Manage Email Alerts